CGCamilla Gustafsen

Camilla Gustafsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Camilla Gustafsen has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PCSK9 deficiency alters brain lipid composition without affecting brain development and function

    by Angela Pärn, Ditte Olsen, Jürgen Tuvikene, Mathias Kaas, Ekaterina Borisova, Mesut Bilgin, Mie Elhauge, Joachim Vilstrup, Peder Madsen, Mateusz C. Ambrozkiewicz, et al.

    PCSK9 induces lysosomal degradation of the low-density lipoprotein (LDL) receptor (LDLR) in the liver, hereby preventing removal of LDL cholesterol from the circulation. Accordingly, PCSK9 inhibitory antibodies and siRNA potently reduce LDL cholesterol to unprecedented low levels and are approved for treatment of hypercholesterolemia. In addition, PCSK9 inactivation alters the levels of several other circulating lipid classes and species. Brain function is critically influenced by cholesterol and lipid composition. However, it remains unclear how the brain is affected long-term by the reduction in circulating lipids as achieved with potent lipid lowering therapeutics such as PCSK9 inhibitors. Furthermore, it is unknown if locally expressed PCSK9 affects neuronal circuits through regulation of receptor levels. We have studied the effect of lifelong low peripheral cholesterol levels on brain lipid composition and behavior in adult PCSK9 KO mice. In addition, we studied the effect of PCSK9 on neurons in culture and in vivo in the developing cerebral cortex. We found that PCSK9 reduced LDLR and neurite complexity in cultured neurons, but neither PCSK9 KO nor overexpression affected cortical development in vivo. Interestingly, PCSK9 deficiency resulted in changes of several lipid classes in the adult cortex and cerebellum. Despite the observed changes, PCSK9 KO mice had unchanged behavior compared to WT controls. In conclusion, our findings demonstrate that altered PCSK9 levels do not compromise brain development or function in mice, and are in line with clinical trials showing that PCSK9 inhibitors have no adverse effects on cognitive function.


  • Open Access

    Heparan sulfate proteoglycans present PCSK9 to the LDL receptor

    by Camilla Gustafsen, Ditte Olsen, Joachim Vilstrup, Signe Lund, Anika Reinhardt, Niels Wellner, Torben Larsen, Christian B. F. Andersen, Kathrin Weyer, Jin-Ping Li, et al.

    Coronary artery disease is the main cause of death worldwide and accelerated by increased plasma levels of cholesterol-rich low-density lipoprotein particles (LDL). Circulating PCSK9 contributes to coronary artery disease by inducing lysosomal degradation of the LDL receptor (LDLR) in the liver and thereby reducing LDL clearance. Here, we show that liver heparan sulfate proteoglycans are PCSK9 receptors and essential for PCSK9-induced LDLR degradation. The heparan sulfate-binding site is located in the PCSK9 prodomain and formed by surface-exposed basic residues interacting with trisulfated heparan sulfate disaccharide repeats. Accordingly, heparan sulfate mimetics and monoclonal antibodies directed against the heparan sulfate-binding site are potent PCSK9 inhibitors. We propose that heparan sulfate proteoglycans lining the hepatocyte surface capture PCSK9 and facilitates subsequent PCSK9:LDLR complex formation. Our findings provide new insights into LDL biology and show that targeting PCSK9 using heparan sulfate mimetics is a potential therapeutic strategy in coronary artery disease.


  • Open Access

    Increased serum levels of sortilin are associated with depression and correlated with BDNF and VEGF

    by H N Buttenschøn, D Demontis, M Kaas, B Elfving, S Mølgaard, C Gustafsen, L Kaerlev, C M Petersen, A D Børglum, O Mors, et al.

    Neurotrophic factors have been investigated in relation to depression. The aim of the present study was to widen this focus to sortilin, a receptor involved in neurotrophic signalling. The serum sortilin level was investigated in 152 individuals with depression and 216 control individuals, and eight genetic markers located within the SORT1 gene were successfully analysed for association with depression. Genotyping was performed using the Sequenom MassARRAY platform. All the individuals returned a questionnaire and participated in a semi-structured diagnostic interview. Sortilin levels were measured by immunoassay, and potential determinants of the serum sortilin level were assessed by generalized linear models. Serum levels of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) were measured in previous studies. We identified a significant increase of serum sortilin levels in depressed individuals compared with controls (P=0.0002) and significant positive correlation between serum sortilin levels and the corresponding levels of BDNF and VEGF. None of the genotyped SNPs were associated with depression. Additional analyses showed that the serum sortilin level was influenced by several other factors. Alcohol intake and body mass index, as well as depression, serum BDNF and serum VEGF were identified as predictors of serum sortilin levels in our final multivariate model. In conclusion, the results suggest a role of circulating sortilin in depression which may relate to altered activity of neurotrophic factors.


  • Open Access

    SorLA Complement-type Repeat Domains Protect the Amyloid Precursor Protein against Processing

    by Arnela Mehmedbasic, Sofie K. Christensen, Jonas Nilsson, Ulla Rüetschi, Camilla Gustafsen, Annemarie Svane Aavild Poulsen, Rikke W. Rasmussen, Anja N. Fjorback, Göran Larson, Olav M. Andersen


  • SorCS2 Regulates Dopaminergic Wiring and Is Processed into an Apoptotic Two-Chain Receptor in Peripheral Glia

    by Simon Glerup, Ditte Olsen, Christian B. Vaegter, Camilla Gustafsen, Susanne S. Sjoegaard, Guido Hermey, Mads Kjolby, Simon Molgaard, Maj Ulrichsen, Simon Boggild, et al.


  • The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion

    by Camilla Gustafsen, Mads Kjolby, Mette Nyegaard, Manuel Mattheisen, Jesper Lundhede, Henriette Buttenschøn, Ole Mors, Jacob F. Bentzon, Peder Madsen, Anders Nykjaer, et al.


  • Open Access

    The pro-neurotrophin receptor sortilin is a major neuronal APOE receptor for catabolism of amyloid-β peptide in the brain

    by Anne-Sophie Carlo, Camilla Gustafsen, Guido Mastrobuoni, Morten Nielsen, Stefan Kempa, Claus Munck Petersen, Thomas Willnow


  • Open Access

    The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain

    by Anne-Sophie Carlo, Camilla Gustafsen, Guido Mastrobuoni, Morten S. Nielsen, Tilman Burgert, Daniela Hartl, Michael Rohe, Anders Nykjaer, Joachim Herz, Joerg Heeren, et al.

    Apolipoprotein E (APOE) is the major risk factor for sporadic Alzheimer's disease. Among other functions, APOE is proposed to sequester neurotoxic amyloid-β (Aβ) peptides in the brain, delivering them to cellular catabolism via neuronal APOE receptors. Still, the receptors involved in this process remain controversial. Here, we identified the pro-neurotrophin receptor sortilin as major endocytic pathway for clearance of APOE/Aβ complexes in neurons. Sortilin binds APOE with high affinity. Lack of receptor expression in mice results in accumulation of APOE and of Aβ in the brain and in aggravated plaque burden. Also, primary neurons lacking sortilin exhibit significantly impaired uptake of APOE/Aβ complexes despite proper expression of other APOE receptors. Despite higher than normal brain APOE levels, sortilin-deficient animals display anomalies in brain lipid metabolism (e.g., accumulation of sulfatides) seen in APOE-deficient mice, indicating functional deficiency in cellular APOE uptake pathways. Together, our findings identified sortilin as an essential neuronal pathway for APOE-containing lipoproteinsin vivoand suggest an intriguing link between Aβ catabolism and pro-neurotrophin signaling converging on this receptor.


  • Open Access

    Sortilin and SorLA Display Distinct Roles in Processing and Trafficking of Amyloid Precursor Protein

    by Camilla Gustafsen, Simon Glerup, Lone Tjener Pallesen, Ditte Olsen, Olav M. Andersen, Anders Nykjær, Peder Madsen, Claus Munck Petersen

    The development and progression of Alzheimer's disease is linked to excessive production of toxic amyloid-β peptide, initiated by β-secretase cleavage of the amyloid precursor protein (APP). In contrast, soluble APPα (sAPPα) generated by the α-secretase is known to stimulate dendritic branching and enhance synaptic function. Regulation of APP processing, and the shift from neurotrophic to neurotoxic APP metabolism remains poorly understood, but the cellular localization of APP and its interaction with various receptors is considered important. We here identify sortilin as a novel APP interaction partner. Like the related APP receptor SorLA, sortilin is highly expressed in the CNS, but whereas SorLA mainly colocalizes with APP in the soma, sortilin interacts with APP in neurites. The presence of sortilin promotes α-secretase cleavage of APP, unlike SorLA, which inhibits the generation of all soluble products. Also, sortilin and SorLA both bind and mediate internalization of sAPP but to different cellular compartments. The interaction involves the 6A domain of APP, present in both neuronal and non-neuronal APP isoforms. This is important as sAPP receptors described so far only bind the non-neuronal isoforms, leaving SorLA and sortilin as the only receptors for sAPP generated by neurons. Together, our findings establish sortilin, as a novel APP interaction partner that influences both production and cellular uptake of sAPP.


  • Subcellular Fractionation of Mouse Brain Homogenates

    by Ditte Olsen, Camilla Gustafsen